Thermo Fisher Scientific Inc., the world leader in serving science, has successfully secured $192,500,000 in new investment capital from investors. This significant funding round underscores continued confidence in the company's robust market position and long-term strategic vision.
With annual revenue of approximately $40 billion, Thermo Fisher Scientific is dedicated to enabling its customers to make the world healthier, cleaner, and safer. The company supports a vast array of scientific endeavors, ranging from accelerating life sciences research and solving complex analytical challenges to increasing laboratory productivity and improving patient health through diagnostics and the development of life-changing therapies. Its comprehensive offerings are delivered through industry-leading brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and PPD.
The capital raised in this funding round will provide Thermo Fisher Scientific with substantial resources to further its strategic objectives. While specific allocation details were not disclosed, the company plans to deploy these funds towards strategic growth initiatives that align with its core mission. This may include investments in enhancing its innovative technologies, expanding global infrastructure, and supporting ongoing research and development efforts across its diverse portfolio of scientific solutions.
This injection of capital positions Thermo Fisher Scientific to continue its trajectory of growth and innovation. The company remains committed to empowering its global team to deliver unrivaled combinations of advanced technologies, purchasing convenience, and pharmaceutical services, solidifying its leadership in the scientific and healthcare industries for years to come.
